Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
PLYX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 22, 2026
Report Source: 2026 1st Quarter Report
Polaryx Therapeutics, Inc. Stock Analysis PLYX
United States Health Care Micro Cap Report: Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. The company is headquartered in Paramus, New Jersey and currently employs 9 full-time employees. The company went IPO on 2026-02-02. Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Read More Polaryx Therapeutics, Inc (PLYX) Chart
Key Statistics of Polaryx Therapeutics, Inc (PLYX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$2.40Volume
58.94KP/E Ratio (TTM)
-52 Week Range
Market Cap
186.53MAvg. Volume
307.91KDividend Yield
-Financial Metrics & Statements of Polaryx Therapeutics, Inc (PLYX)
FAQ's for Polaryx Therapeutics, Inc (PLYX)
- According to Musaffa’s Shariah screening methodology, Polaryx Therapeutics, Inc (PLYX) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Polaryx Therapeutics, Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Polaryx Therapeutics, Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Polaryx Therapeutics, Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Polaryx Therapeutics, Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Polaryx Therapeutics, Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.